Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress

Radoslaw Magierski¹, Tomasz Sobow², Emilia Schwertner³ and Dorota Religa³,4*

1 Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Lodz, Poland, 2 Dialog Therapy Centre, Warsaw Institute of Psychology, University of Lodz, Lodz, Poland, 3 Center for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden, 4 Tema Aging, Karolinska University Hospital, Stockholm, Sweden

The core symptoms of different dementia subtypes are the behavioral and psychological symptoms of dementia (BPSD) and its neuropsychiatric symptoms (NPS). BPSD symptoms may occur at any stage in the case of dementia due to Alzheimer’s disease (AD), whereas they tend to occur early on in the case of its behavioral variant frontotemporal dementia or dementia with Lewy bodies and are essential for diagnosis. BPSD treatment consists of non-pharmacological as well as pharmacological interventions, with non-pharmacological interactions being suggested as first-line treatment. Agitation, psychotic features, apathy, depression, and anxiety may not respond to acetylcholinesterase inhibitors or memantine in AD cases; therefore, antipsychotics, antidepressants, sedative drugs or anxiolytics, and antiepileptic drugs are typically prescribed. However, such management of BPSD can be complicated by hypersensitivity to antipsychotic drugs, as observed in DLB, and a lack of effective pro-cognitive treatment in the case of frontotemporal dementia. The present paper reviews current knowledge of the management of BPSD and its limitations and discusses ongoing clinical trials and future therapeutic options.

Keywords: behavioral and psychological symptoms of dementia, neuropsychiatric symptoms, antipsychotics, antidepressants, non-pharmacological interventions, clinical trial

INTRODUCTION

The commonly-observed core symptoms of dementia are classified as behavioral and psychological symptoms of dementia (BPSD) or as neuropsychiatric symptoms (NPS) (Zhao et al., 2016). NPS are mainly associated with Alzheimer’s dementia (AD), but they can occur in various types of dementia, as well as in mild cognitive impairment (MCI) (Siafarikas et al., 2018). NPS have been recognized as a risk factor of dementia among individuals with MCI, especially when co-occurring with affective and psychotic symptoms (Liew, 2019). Moreover, cases characterized by behavioral changes and psychiatric symptoms, but without cognitive impairment in later life, have been described as mild behavioral impairment (Taragano et al., 2009); this has been recognized as an at-risk state for
cognitive decline and dementia, biomarker of cognitive decline, or even a potential manifestation of prodomal dementia (Ismail et al., 2018; Taragano et al., 2018; Creese et al., 2019). While NPS impair the quality of life of both patient and caregiver, they seem to exert the strongest impact on the latter (Feast et al., 2016; Terum et al., 2017) and may influence the decision regarding nursing home placement (Porter et al., 2016; Vandepitte et al., 2018). In addition, together with the severity of dementia, the presence of NPS contributes to increasing care costs (Rattinger et al., 2015; Wübker et al., 2015; Rattinger et al., 2019).

NPS have a high prevalence index, and different patterns of symptoms are observed depending on the course of the illness, biological factors, diagnosis, age of onset, dementia severity, and place of residence of patients (Lyketsos et al., 2000; Tractenberg et al., 2003; Ryu et al., 2005; Ballard, 2007; Peters et al., 2012; van der Linde et al., 2012; Borsje et al., 2015; Mulders et al., 2016; van der Linde et al., 2016; Bauhuis et al., 2018; Rozum et al., 2019). A good example is AD, in which NPS are extremely common: apathy is the most frequent symptom, followed by depression, aggression, anxiety, and sleep disorder (Zhao et al., 2016). Other symptoms, such as irritability, appetite disorder, aberrant motor behavior, delusion, disinhibition, and hallucination are less common, with their prevalence ranging from 36 to 16% of AD cases. Therefore, it is necessary to implement effective strategies against NPS and their unavoidable serious consequences.

The aim of the paper is to review current knowledge, limitations, and practices regarding the management of BPSD and to discuss on-going clinical trials and future therapeutic options.

**REVIEW OF CURRENT KNOWLEDGE ON BPSD MANAGEMENT**

**Non-Pharmacological Strategies**

A number of non-pharmacological techniques are used in medicine, specifically in the late-life population, a number of which have been found to be effective at treating neuropsychiatric symptoms (Gitlin et al., 2009; Abraha et al., 2017); however, the quality of evidence for such interventions is low (Wang G. et al., 2018), and there is limited evidence for recommending their use in general (Cabrera et al., 2015). As recent papers on non-pharmacological interventions have higher reporting quality than older ones, it is likely that our knowledge on the role of non-pharmacological interventions will be steadily improved as more studies are performed (Horr et al., 2015).

Non-pharmacological approaches comprise various types of intervention: sensory stimulation (acupressure, aromatherapy, massage, touch therapy, light therapy, garden activities, music and dance therapy, and snoezelen multisensory stimulation therapy), cognitive and emotion-oriented approaches (cognitive stimulation, reminiscence therapy, validation therapy, and simulated presence therapy), behavior management techniques, multicomponent interventions, and other therapies (education of patients and caregivers, exercise, and animal-assisted therapy involving real or robotic animals) (Abraha et al., 2017). Non-pharmacological strategies were even found to be more effective than pharmacological treatments (Yury and Fisher, 2007; Brodaty and Arasaratnam, 2012; Schneider et al., 2006a) and appear to have fewer adverse effects than pharmacotherapy with antipsychotics (Dyer et al., 2018). Moreover, a meta-analysis found such interventions to prove useful, versatile, and potentially cost-effective in improving outcomes and quality of life in individuals with dementia and their carers (Olazarán et al., 2010).

However, in practice, the widespread use of nonpharmacological strategies is beset by many difficulties, the main ones being lack of trained personnel, limited knowledge on the efficacy of nonpharmacological interventions, staff opinions and preferences, and an expectation of quick resolution of symptoms (Ervin et al., 2014; Jennings et al., 2018). In addition, in the case of severe agitation, or other emergency situations where patients may be endangering themselves or others, pharmacological intervention has priority. In typical situations, current evidence suggests that nonpharmacological techniques should be used as a first-line option for NPS and that many clinical guidelines recommend starting with such management (Dyer et al., 2018).

This part of the review will focus on recent advancements in non-pharmacological management (NPM) and discuss other approaches a reader can find in previous works (see Meyer and O’Keefe, 2018).

As NPM supports mainstream therapy in alleviating symptoms and improving the quality of life of patients, both approaches should be considered as parts of a broader concept of person-centered care (PPC). PPC, by supporting the personhood of patients and understanding their experience, attempts to assist them and their family in reaching the best possible quality of life (Molony et al., 2018).

The well-being of a patient with dementia can be achieved through understanding the individual needs and history of each patient. Similarly, to successfully reduce its occurrence, the underlying cause of the symptom also has to be understood. NPS can stem either from neurocognitive impairment associated with dementia or from the unmet needs of the patient; therefore, the possible interplay between these factors should be addressed while planning intervention.

In cases of dementia where cognitive functions are impaired, patients lose their ability to communicate through language. In such cases, they can still manifest their needs, such as pain, hunger, boredom, insecurity, or anxiety, through their behavior. However, such behavior may be influenced by their cognitive impairment, which affects the way they perceive, interpret, and react to the environment: patients may have problems with explicit memory, recognition of visual motion or spatial orientation, and topographic disorientation (Zwijnen et al., 2016). A greater understanding of the mechanisms underpinning behavior can serve as a basis for more precise interventions.

Non-pharmacological interventions can be divided into direct ones targeted at patients and indirect ones targeted at their environment (Caspar et al., 2018).
Direct interventions attempt to address the needs of the patient and can include lifestyle modification (e.g., diet, activity programs) or psychological therapy (art therapy, humor, animal, or PARO robotic pets assisted therapy); in contrast, indirect interventions involve either modification of the physical environment such as room temperature, light and noise levels, or familiarity or educating caregivers and reducing the stress and burden placed on them (Marniott et al., 2000; Soril et al., 2014).

One of the most distressing symptoms for caregivers is agitation, or aggression, which also is one of the most common reasons for antipsychotic prescription. However, antipsychotic use is associated with a high risk of adverse effects (Farlow and Shamiyian, 2017), and there is an urgent need to define efficient strategies to reduce their occurrence.

Between 45 and 80% of patients with dementia in nursing homes suffer from chronic pain. Impaired cognitive functions limit the possibility of communicating pain and thereby increase the risk of this pain of being underdiagnosed and untreated (Hadjistavropoulos et al., 2007). Similarly, lack of activity concerns up to 90% of patients with dementia residing in nursing homes: A problem that has been consequently raised by researchers since 1995 (Nolan et al., 1995; Hancock et al., 2006). Pain and boredom are important determinants of agitation (Kolanowski et al., 2017), and interventions directing them have been explored as a potential way to lower the level of agitation. In one study, nursing home residents were visited by a pair of elder-clowns for approximately 10 min, twice a week, for 12 weeks. The clowns interacted with the patients using improvisation, humor, empathy, and expressive modalities such as songs, musical instruments, and dance. At the end of the intervention, the total NPI-NH scores were found to have declined significantly, and a general reduction of agitation was observed (Kontos et al., 2016).

In another study, a group of patients treated with 8 weeks of pain management demonstrated significantly lower agitation and aggression in comparison with controls (Husebo et al., 2011; Husebo et al., 2014).

PARO robotic pets, in use since 2003, have proven successful in lowering stress, depression, and anxiety in patients with dementia. Intervention with a robotic pet three times weekly per 20 min was found to reduce the need for pain medications and psychoactive medication (Petersen et al., 2017).

No significant improvement in total NPI score was observed after 3 months of supplementation with nutraceutical formulation (NF) [folate, alpha-tocopherol, B12, S-adenosyl methionine (SAM) N-acetyl cysteine (NAC), and acetyl-L-carnitine (ALCAR)] as part of the Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer’s Disease (Remington et al., 2015).

Another group of interventions are those that directly focus on supporting the identity of the patients with dementia. In 2011, Caddell and Clare reviewed existing interventions and identified 10 studies aimed at promoting the preservation of patient identity. Although all interventions reported benefits to the patients, the considerable heterogeneity of patients and methodologies used in the study do not allow any firm conclusions to be drawn (Caddell and Clare, 2011). A promising area of research attempts to enhance and enrich the strategies used by patients to cope with cognitive impairment to promote well-being in the early stages of dementia. The spectrum of responses to problems with memory has been proposed to range from ‘self-maintaining’ to ‘self-adjusting’ (Clare, 2003). While patients following a self-maintaining strategy attempt to maintain the prediagnosis concept of self, those with a self-adjusting stance adapt a self-concept based on the challenges associated with the memory decline. A Preserving Identity and Planning for Advance Care (PIPAC) intervention combines these two components. The self-maintaining (reminiscence-based) component includes documenting an identity-salient role from the life history of the patient with the aim of describing what it meant to patients to “live well” in the past. The self-adjusting component is incorporated into a discussion of advance care planning (ACP), in which the patients focus on what it means for them to ‘live well’ in the future. They are informed about treatment options and how care decisions are made and rehearse communicating their preferences to relatives. After intervention, authors observed lower depressive symptoms and illness burden and greater quality of life and health-related indicators of well-being (Hilgeman et al., 2014).

Studies suggest that a combination of both direct and indirect non-pharmacological interventions may be essential in order to alleviate BPSD. Moreover, a recent study on health-related quality of life (HRQL) for people with dementia found antipsychotic discontinuation to have a detrimental effect on HRQL. This negative impact was, however, mitigated by social interactions (Ballard et al., 2017).

For intervention to be successful, it should consider the importance of a caring environment, i.e., the physical, built one, and the social environment, as well as care skill development and maintenance, and taking an individualized approach to each patient (Caspar et al., 2018).

Pharmacological Treatments

Currently, non-pharmacological and pharmacological management options exist for treating NPSs. Of the two, pharmacological intervention seems to be the ideal solution, mainly from the perspective of the caregiver. Oral dosage form administration is quick and easier than non-pharmacological interventions; in addition, it does not require professional staff involvement and allows the strength of the effect to be changed by increasing the dose of the drug. Moreover, in real life, some caregivers are interested in the possibility of administering the drug in the form of a solution without informing the patient.

Pharmacological interventions have many limitations in specific populations such as elderly patients with dementia and behavioral symptoms.

A key problem is the relatively small number of randomised clinical trials, most of which have been carried out on a narrowly defined indication, such as apathy, depression, or anxiety: some publications employ general terms such as psychiatric symptoms, while others use very detailed ones such as apathy in patients...
with Huntington’s disease. Neuropsychiatric symptoms, on the other hand, occur in the majority of types of dementia, not just Alzheimer’s disease (AD). In addition to AD, studies on DLB, PDD and frontotemporal lobe degeneration have also been performed; however, many of the observations on the efficacy of psychotropics in behavioral changes are based on studies conducted in other age groups with different clinical characteristics. Most research focuses on the effectiveness of antipsychotics, mood stabilizers and antidepressants in treating NPSs, and cholinesterase inhibitors and memantine in the case of AD.

Only a few drugs are indicated for treating NPSs in dementia. Tiapride is recommended for agitation in cases with dementia in Poland, and pimavanserin for psychosis associated with Parkinson’s disease in the USA. In addition, risperidone is recommended for treating persistent aggression in moderate-to-severe cases of AD not responding to non-pharmacological interventions and when there is a risk of harm to the patient; however, treatment should be restricted to 6 weeks (Canada and Europe). Finally, quetiapine is recommended for psychiatric symptoms in patients with dementia; this indication is covered by public insurance in Poland (Lanctôt et al., 2017). Although prescribing psychotropic medications to a patient with dementia appears to be clinically justified, it still remains an off-label order in most countries.

Secondly, a minority of interventions with psychotropic drugs for NPSs in nursing homes is fully appropriate (van der Spek et al., 2016). A difference between correctness of use of antidepressants (used mostly appropriately) and anticonvulsants (used mostly inappropriately) was noticed. Unfortunately, for many (frequently unclear) reasons, the main method of pharmacological treatment of NPSs is based on antipsychotics. Antipsychotics are disproportionately often used in older populations (Colenda et al., 2002; Nijk et al., 2009; Gulla et al., 2016; Maust et al., 2017) for various indications, not only psychosis. Many physicians believe that antipsychotics are multipotential: they may also be effective in other clinical conditions, and their primary activity does not concern psychoses. Therefore, their prescription is reasonable in patients with delusions, hallucinations, or psychotic anxiety (Sultzter et al., 2008). Even if prescribing a neuroleptic to a person with dementia appears to be clinically justified, it still remains an off-label order in most countries (Maglione et al., 2011). In many cases, neuroleptics act mainly via a non-specific sedative effect and serve as a form of chemical restraint: efficacy data indicates that for all atypical antipsychotics show at best modest benefit against neuropsychiatric symptoms observed in cases with dementia (Seitz et al., 2013).

Thirdly, antipsychotics have been consistently associated with serious adverse effects and increased mortality in patients with dementia (Schneider et al., 2005; Ma et al., 2014; Schneider et al., 2006a; Kales et al., 2012; Ralph and Espinet, 2018), with the risk being dose-dependent (Maust et al., 2015). Increased mortality is related to a range of interacting factors, and the precise mechanisms of death are still uncertain. Antipsychotic treatment can result in cerebrovascular events (e.g., stroke), cardiovascular effects (e.g., orthostatic hypotension, cardiac arrhythmias, and QTc prolongation), metabolic effects, extrapyramidal symptoms and falls, as well as pneumonia (Steinberg and Lyketsos, 2012).

The growing body of evidence regarding the increased risk related to antipsychotic use among patients with dementia resulted in black box warnings being issued by the FDA for atypical drugs (in 2005) and conventional drugs (in 2008), and as experts’ recommendations (Herrmann et al., 2013; Ihl et al., 2015). However, these guidelines have had little impact on prescribing psychotropics in some practices (Desai et al., 2012; Craig et al., 2016) and with positive trends in others, such as Danish residents aged ≥65 years (Nørgaard et al., 2016). The drug may often be prescribed in response to the request of a caregiver, family member, or member of staff.

Finally, overuse of antipsychotics has been reported (Rios et al., 2017), and some measures for limiting such practices have been undertaken (Jessop et al., 2017; Kirkham et al., 2017).

However, while long-term antipsychotic treatment is known to be associated with an increased risk of mortality, their use may be justified by circumstances. Even if the decision to implement the treatment may be clinically justified, regular attempts to withdraw these drugs are recommended in guidelines (Azermai et al., 2012), and practical algorithms have been proposed for process of drug discontinuation (Miarons et al., 2017). Even so, withdrawal of these drugs has consequences, especially after long-term use, including the obvious risk of re-aggravation of NPSs. A meta-analysis published by Declercq et al. indicates that AD patients can be withdrawn from chronic antipsychotic medication without demonstrating detrimental effects on their behavior (Declercq et al., 2013); however, the precise effects of withdrawal on patient cognition, adverse events, quality of life, and decrease in mortality remain unknown (Van Leeuwen et al., 2018).

Agitation

Agitation is quite a common problem in patients with Alzheimer-type dementia but may also occur in other types of dementing illnesses. Although non-pharmacological treatments represent first-line options, they are often of limited efficacy. This fact may explain why various categories of psychotropic drugs are used for treatment of agitation in dementia. These include typical (promazine) and atypical antipsychotics, antidepressants, anticonvulsants, antihistaminergic drugs (hydroxyzine), and herbal preparations. Most of these are off-label psychotropic medications, because there is insufficient or no data for their efficacy and safety in patients with dementia, and their prescription is based on tradition and personal opinions of physicians. Most worringly, their use may entail serious adverse effects (SAEs). For example, a recent Cochrane meta-analysis (Baillon et al., 2018) suggests that valproate preparations, which are widely used for “organic brain disorders”, may well be ineffective at treating agitation in people with dementia. The treatment has a high rate of adverse effects, associated with possible SAEs, and hence valproate cannot be recommended for management of agitation in dementia.
Few papers have been published on the efficacy of antidepressants in agitation and psychosis in patients with dementia. A Cochrane meta-analysis concluded that the citalopram and sertraline were more effective in reducing symptoms of agitation compared to placebo in two studies (Seitz et al., 2011). SSRIs and trazodone were also found to be well tolerated when compared to typical and atypical antipsychotics. In addition, no differences were observed between antidepressants and typical or atypical antipsychotics in terms of efficacy.

A recent systematic review and meta-analysis of RCTs performed to determine the most efficacious and acceptable treatments of agitation in dementia found that haloperidol demonstrated little efficacy compared to placebo, despite its relatively widespread use for alleviating agitation (Kongpakwattana et al., 2018). In addition, dextromethorphan/quinidine and risperidone were significantly more efficacious than placebo, as were SSRIs when considered as a class, but not when analyzed individually.

Moreover, some completed randomized controlled trials (RCTs) on treating agitation in dementia of Alzheimer-type with new or repositioned drugs have been published recently (Porsteinsson and Antonsdottir, 2017). Considering the available data on drug efficacy, adverse effects, availability, and novel drug registration procedures, it seems that citalopram may be the treatment period registration procedures, it seems that citalopram may be the best sensible option for many physicians in controlling agitation in AD (Porsteinsson et al., 2014). However, the treatment period should be at least nine weeks long to allow enough time for full response (Wintraub et al., 2015). An alternate algorithm of drug treatment for agitation and aggression associated with AD or mixed dementia was proposed by Davies et al. (2018). The authors recommend starting treatment with risperidone, then aripiprazole or quetiapine, followed by carbamazepine and then citalopram. In the case of citalopram prescription, it is important to be aware of the increased risk of QTc prolongation, which can be problematic in geriatric patients. Promising novel and/or repositioned drugs intended for agitation in dementia are characterized in Tables 1 and 2.

An alternative method of treating agitation in dementia is by electroconvulsive therapy (ECT). A recent review of papers investigating the use of ECT for treating agitation in dementia (Glass et al., 2017) identified 11 papers, with a total number of 216 patients. The studies indicate promising results in decreasing agitation in patients with dementia; however, the studies have many methodological limitations regarding the type of study, use of psychotropic medications, choice of scales, lack of control group and number of patients, among others.

**Psychotic Features**

Most psychosis symptoms that occur in dementia are hallucinations and delusions, and many patients require antipsychotic treatment to deal with of such distressing psychiatric symptoms. This is especially true when a patient acts on the delusions, experiences significant fear, or if their safety is threatened.

Antipsychotics are still widely prescribed, even in cases of dementia without psychosis. While a decline of first generation antipsychotic drug prescriptions was observed following a UK National Guidance and Drug Safety Warning, by the National Institute for Health and Care Excellence, the decreasing trend in second-generation drug prescriptions has been halted by the increased prescription of risperidone (Stocks et al., 2017).

In 2016, the American Psychiatric Association published a set of Practice Guidelines on the use of antipsychotics to treat agitation or psychosis in dementia (Reus et al., 2016). The guidelines comprise 15 statements on antipsychotic use in dementia, grouped into five sections: assessment of behavioral/psychological symptoms of dementia; development of a comprehensive treatment plan; assessment of benefits and risks of antipsychotic treatment for the patient; dosing, duration, and monitoring of antipsychotic treatment; and use of specific antipsychotic medications depending on clinical context. Although Reus et al. (2016) indicate that “guidelines should not be considered as a statement of the standard of care or inclusive of all proper treatments or methods of care”, such guidance regarding the method of assessing the need for antipsychotic treatment and monitoring results may nevertheless be of value to clinicians.

The efficacy and safety of the antipsychotics olanzapine, quetiapine, and risperidone in treating dementia were examined in the CATIE-AD study (Ismail et al., 2007; Sultzer et al., 2008; Schneider et al., 2006b). Other second-generation antipsychotics, such as aripiprazole and ziprasidone, have also demonstrated safety and efficacy in treating AD (De Deyn et al., 2005; Rocha et al., 2006; Mintzer et al., 2007; Streim et al., 2008), as well as in dementia with Lewy Bodies (Lee and Shen, 2017; Sugawara Kikuchi and Shimizu, 2019), where neuroleptic treatment is problematic due to neuroleptic hypersensitivity.

Currently, more data is needed to conclusively determine whether different atypical antipsychotics vary with regard to their effectiveness, or their risk of mortality or cerebrovascular events (Yunusa et al., 2019). Newer drugs such as pimavanserin in synucleinopathies and brexiprazole are undergoing evaluation in various populations of patients with dementia (Table 1).

**Apathy**

Apathy is a non-cognitive symptom and one of the most prevalent behavioral and psychological symptoms of dementia, which can be observed even at the prodromal stage (Sherman et al., 2018). It can be characterized as diminished motivation or even lack of motivation and loss of initiative. Apathy is a longlasting state that is associated with increased mortality and a substantially greater burden for caregivers (Harrison et al., 2016; Camargo et al., 2016; Nijsten et al., 2017; Terum et al., 2017); however, a Japanese study found apathy, anxiety, and depression not to seriously aggravate caregiver burnout. A higher level of burnout was related to agitation/aggression, irritability, aberrant motor behavior, and hallucinations (Hiyoshi-Taniguchi et al., 2018).

Although our understanding of the underlying neuronal basis of apathy has improved in recent years, the effectiveness of treatment is still limited (Huey et al., 2017; Lansdall et al., 2017; Ducharme et al., 2018; Fernández-Matarrúa et al., 2018; Kumfor et al., 2018). The treatment of apathy includes...
TABLE 1 | Current studies on pharmacological treatment of agitation and psychosis in dementia with novel drugs [data available at: ClinicalTrials.gov (accessed June 30, 2020); filters used: agitation, psychosis, and dementia; Studies: recruiting; not yet recruiting; active, not recruiting; enrolling by invitation]; PLC, placebo; PD, Parkinson’s disease; AD, Alzheimer’s disease; FTD, fronto-temporal dementia.

| Name                          | Mechanism of action                                      | Study population                  | Treatment                                                  | Results/status of the study                                                                 | Study ID (ClinicalTrial.gov) or reference |
|-------------------------------|----------------------------------------------------------|-----------------------------------|-----------------------------------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------|
| Pimavanserin                  | A selective 5-hydroxytryptamine (HT)2A receptor inverse agonist/antagonist | PD psychosis                      | Pimavanserin 34 mg vs. PLC                                | Significant improvement with pimavanserin vs. PLC (-5.79 decrease in SAPS-PD scores in pimavanserin group compared with -2.73 for PLC (difference -3.06; 95% CI -4.91 to -1.20; p=0.001; Cohen’s d 0.50)) | ACP-103-020; (Cummings et al., 2014) |
|                               |                                                          | AD psychosis                      | Pimavanserin 34 mg vs. PLC                                | Significant improvement for pimavanserin Primary endpoint (week 6); Mean change in the Neuropsychiatric Inventory-Nursing Home version psychosis score Pimavanserin versus PLC: -3.76 points (SE 0.65) versus -1.93 points (0.63) (mean difference -1.84 [95% CI -3.64 to -0.04]; Cohen’s d=-0.32; p=0.045); No significant advantage for pimavanserin versus PLC at week 12 (treatment difference -0.51 [95% CI -2.23 to 1.21]; p=0.561); | ACP-103-019; (Ballard et al., 2018) |
|                               |                                                          | AD psychosis                      | Pimavanserin 34 mg vs. PLC                                | Significant efficacy in patients with higher baseline severity of psychotic symptoms (delta=-4.43; Cohen’s d=−0.73, p=0.011); Pimavanserin vs PLC: ≥30% improvement was 88.9% vs. 43.3% (p<0.001); ≥50% improvement was 77.8% vs. 43.3% (p=0.008); | ACP-103-019; (Ballard et al., 2019) |
| Dementia-related psychosis    |                                                          | PD psychosis                      | A retrospective chart review                               | No Study Results Posted on ClinicalTrials.gov for this Study; Study has been completed, results have not been published; Clinical improvement in psychosis documented in 76% of patients (69/91) Study has been completed, results have not been published; Study Results have been posted on ClinicalTrials.gov; | NCT03236556; [ACP-103-045]; 2017-002227-13 (EudraCT Number) |
| Scyllo-inositol (ELND005)     | Inhibition of amyloid beta peptide aggregation           | Agitation and aggression in AD    | A prospective, 12-week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe AD agitation and aggression in AD 36-week extension study of Study AG201 | Study has been completed, results have not been published; Study Results have been posted on ClinicalTrials.gov; | NCT01735630; ELND005-AG201 |
|                               |                                                          | Agitation and aggression in AD    | 3 mg of mibampator orally twice daily for 12 weeks (may have been reduced to 1 mg if participant was unable to tolerate) vs PLC | Study has been terminated, results have not been published; Study Results have been posted on ClinicalTrials.gov; No significant group differences; mibampator was significantly better (p = 0.007) than PLC only on the Frontal Systems Behavior Inventory | NCT01766336 |
| Mibampator (LY-451395)        | An amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor potentiator | Agitation and aggression in AD    | 3 mg of mibampator orally twice daily for 12 weeks (may have been reduced to 1 mg if participant was unable to tolerate) vs PLC | Study has been terminated, results have not been published; Study Results have been posted on ClinicalTrials.gov; No significant group differences; mibampator was significantly better (p = 0.007) than PLC only on the Frontal Systems Behavior Inventory | NCT00843518; (Trzepacz et al., 2013) |

(Continued)
TABLE 1 | Continued

| Name | Mechanism of action | Study population | Treatment | Results/status of the study |
|------|---------------------|------------------|-----------|-----------------------------|
| Lumateperone (ITI-007) | A potent 5-HT2A antagonist, a mesolimbic/mesocortical dopamine pre-synaptic partial agonist and post-synaptic antagonist activity at D2, glutamate GluN2B receptor phosphoprotein modulator with D1-dependent enhancement of both NMDA and AMPA currents via mTOR protein pathway and an inhibitor of serotonin reuptake | Agitation in patients with dementia, Alzheimer's disease, FTD (Deakin et al., 2004; Callegari et al., 2016), while paroxetine, was associated with a significant reduction of apathy in Parkinson's disease (Sepehr et al., 2017; Ruthirakuan et al., 2018). Agomelatine, but not paroxetine, was associated with a significant reduction of apathy in Alzheimer's disease (Gelderblom et al., 2017). Apathy is a substantial part of clinical picture of Parkinson's disease (den Brok et al., 2015), Parkinson's disease dementia, and dementia with Lewy bodies, significantly affecting the course of the disease in the case of the latter (Breitve et al., 2018). However, no efficacious treatment currently is known to exist (Santangelo et al., 2013; Holguin Lew et al., 2017). Depression Depression is inextricably linked to cognitive disorders and dementia. Over the years, there has been a discussion about the relationship between depression and dementia (Bennett and Thomas, 2014). On the one hand, it was postulated that depression is a risk factor or a causative factor of dementia. On the other hand, depression has been proven to be a typical presentation of the initial phases of dementia or MCI and is in fact part of the clinical picture of dementia. There is also a proposal that antidepressant treatment is responsible for the occurrence of dementia (Lee et al., 2016; Moraros et al., 2017; Wang C. et al., 2018), especially when inappropriate medication is ised (Heser et al., 2018). Regardless of neuropathological and pathophysiological conditions, depression during dementia is a significant clinical and therapeutic problem with serious consequences for the patients and caregivers. As with all BPSD, the management of clinical depression should start with the optimization of dementia treatment. Unfortunately, while acetylcholinesterase inhibitors and memantine are effective in the symptomatic treatment of AD, current evidence suggests that they have limited efficacy for the treatment of depressive symptoms in dementia. Furthermore, non-pharmacological treatments, which are a preferred initial approach for all NPSs, have limited evidence for depressive symptoms. However, a recent review identified five modifiable relevant factors related to depression in dementia among community-dwelling individuals: pain, neuropsychiatric symptoms, cognitive decline, social isolation, and quality of life; in addition, neuropsychiatric symptoms and quality of life were found to be modifiable factors for patients living in long-term care facilities (Kubo et al., 2019). The authors conclude that...
### TABLE 2 | Current studies on pharmacological treatment of agitation and psychosis in dementia with repositioned drugs [data available at: ClinicalTrials.gov (accessed June 30, 2020); filters used: agitation, psychosis, and dementia; Studies: recruiting; not yet recruiting; active, not recruiting; enrolling by invitation]; PLC, placebo; PD, Parkinson’s disease; AD, Alzheimer’s disease; FTD, frontotemporal dementia.

| Name | Mechanism of action | Study population | Treatment | Results/status of the study | Study ID (ClinicalTrials.gov) or reference |
|------|---------------------|------------------|-----------|----------------------------|------------------------------------------|
| Deuterated (d6)-dextromethorphan/quinidine (AVP-786) | Dextromethorphan - a low-affinity N-methyl-D-aspartate receptor antagonist, e1 receptor agonist, serotonin and norepinephrine reuptake inhibitor, and neuronal nicotinic α3β4 receptor antagonist; Quinidine - an anti-arrhythmic agent blocking voltage-gated sodium channels, inhibitor of cytochrome P450 2D6; Quinidine increases the bioavailability of dextromethorphan and prolongs its effects | Agitation in patients with Alzheimer’s type dementia | A phase 3, 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-design Study (AVP-786 (Dose 1) vs AVP-786 (Dose 1) Vs PLC) | Ongoing (study is recruiting participants) | NCT03393520 |
| Brexpiprazole (OPC-34712) | Second generation antipsychotic | Agitation associated with Alzheimer’s type dementia | A phase 3, 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose trial (three arms: Low Dose Brexpiprazole Arm vs. High Dose Brexpiprazole Arm vs PLC) | Ongoing (studying participants) | NCT03548584 |
| | Agitation associated with Alzheimer’s type dementia | A phase 2/3 multicenter, placebo-controlled, randomized, double-blind, parallel-group Comparison Trial (brexpiprazole 1 mg vs. brexpiprazole 2 mg vs. PLC for 10-week treatment regimen) | The long-term safety and tolerability of oral brexpiprazole in agitation associated with Alzheimer’s type dementia | Ongoing (studying participants) | NCT03620981 |
| Prazosin | Postsynaptic alpha-1 adrenoreceptor antagonist | Agitation associated with Alzheimer’s type dementia | A multicenter, on-label trial of brexpiprazole 1 mg or 2 mg for a 14 week treatment regimen with individualized doses up to a maximum of 4 mg mid-morning and 6 mg at bedtime, or matching PLC capsules | Ongoing (study is recruiting participants) | NCT00161473; NCT01126099; NCT03594123 |
| Cannabinoids | Ligands of cannabinoid receptors CB1 and CB2 | Disruptive agitation in AD | Oral prazosin hydrochloride capsules will be administered twice daily, with individualized doses up to a maximum of 4 mg mid-morning and 6 mg at bedtime, or matching PLC capsules | Prazosin was well tolerated and improved behavioral symptoms in patients with agitation/aggression in AD Study has been completed, results have not been published; study results have been posted on ClinicalTrials.gov; | NCT00161473; NCT01126099 |
| Mirtazapine | Noradrenergic and specific serotonergic tetracyclic antidepressant (NaSSA) | Agitation in dementia | A pragmatic, Multi Centre, 12-week, Double-blind, Placebo Controlled Randomised Trial of mirtazapine vs. PLC. Participants will then be followed up for 1 year after | Ongoing (active, not recruiting) | NCT03328676 |

(Continued)
non-pharmacological interventions improving identified relevant factors may improve symptoms of depression in patients with dementia. Moreover, symptoms of depression and anxiety can be reduced by psychological interventions added to usual care (Orgeta et al., 2014; Orgeta et al., 2015).

While planning to implement non-pharmacological interventions for depression in patients with dementia, it should be considered that the presence of depression may be an important barrier to engagement in therapy, for example, physical activity (Watts et al., 2018).

In the majority of patients, however, pharmacological treatment is the basis of therapy.

A practical question arises whether there is sufficient evidence for recommending the use of pharmacotherapy in treating depression in patients with dementia (Farina et al., 2017; Ford and Almeida, 2017). Serotonergic drugs are a basic option in the treatment of mood disorders in the general population. It seems that they are also a good option for mood disorders in people with cognitive impairment and dementia (Magierski and Sobow, 2016). However, a recent Cochrane meta-analysis found little support for the efficacy of antidepressants for treating depression in dementia (Dudas et al., 2018).

Sleep Problems
Sleep disorders in patients with dementia are frequent, affecting between 25 and 80% of patients; these figures are higher than those associated with healthy aging and are believed to result from neurodegenerative processes (Ohayon et al., 2004; Bombois et al., 2010). The consequences of abnormal sleep in general population are increased risk of cognitive impairment and dementia (Bubu et al., 2017; Shi et al., 2018), but in patients with dementia, consequences include comorbidity, risk of falling, poorer quality of life, and increased psychological, physical, and financial burdens in the caregiver. In addition, sleep disorders are the primary risk factor for nursing home placement, even more so than cognitive impairment. Finally, they often aggravate the course of dementia through drowsiness during the day, thus impairing cognitive performance, driving, and social activities (Tractenberg et al., 2005).

Different sleep disorders are observed depending on the type of dementia (Roth, 2012). Alzheimer’s disease is characterized by an irregular sleep-wake rhythm, sundowning, wandering, and obstructive sleep apnea. PDD is characterized by REM sleep behavior disorder, sleep maintenance insomnia,hypersomnia, restless leg syndrome/periodic limb movements in sleep, while DLB patients demonstrate REM sleep behavior disorder, hypersomnia, periodic limb movements in sleep, and irregular sleep-wake rhythms. Similarly, those observed in FTDs include insomnia, excessive daytime sleepiness, sleep disordered breathing, and less frequent restless leg syndrome (McCarter et al., 2016).

It is difficult, or even impossible, to propose a universal method of treating sleep disorders in dementia due to this significant variation in clinical picture and neuropsychology. Popular drugs for sleep disturbances in dementia include melatonin, trazodone, benzodiazepines, Z-drugs (zolpidem, zopiclone, and zaleplon), and recently registered ramelteon. At this point, it is necessary to recall that elderly benzodiazepine users became more sensitive to their medications. Paradoxical
excitement (increased anxiety, acute excitement, and hyperactivity) can be observed in some cases. Moreover, the Z-drugs have documented night time unrecalled events, which may endanger other residents, and ramelteon may have a delayed onset for therapeutic effects of days. Other treatment modalities include antihistaminergic drugs, herbal preparations, or antidepressants (for example, mianserin and mirtazapine). A Cochrane meta-analysis examining the efficacy of pharmacotherapies for sleep disturbances in dementia found a lack of evidence regarding the issue of sleep problems in dementia (McCleery et al., 2016).

NETWORK META-ANALYSES FOR PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENTS OF BPSD

A sizable number of papers have been published on the effectiveness of different strategies targeting BPSD. As a result, both pharmacological and non-pharmacological methods are recommended through guidelines. Due to the diversity and extentiveness of interventions (exercise versus reminiscence therapy versus antipsychotic use) and the lack of head-to-head trials, it is difficult or even impossible to synthesize and objectify present data. This applies especially to descriptive literature reviews. Network meta-analysis solves this problem, because it allows findings to be analyzed quantitatively and for direct and indirect evidence to be evaluated simultaneously.

Several systematic reviews and network meta-analyses on the efficacy of different strategies for BPSD treatment were published recently. These publications examine the effectiveness of various therapeutic options and make head-to-head comparisons of the effectiveness of the tested drugs (Kongpakwattana et al., 2018).

A comparison of pharmacological and nonpharmacological interventions for treating aggression and agitation in adults with dementia (Watt et al., 2019) found showed that multidisciplinary care, massage and touch therapy, and music combined with massage and touch therapy were clinically more efficacious than usual care. Despite the study limitations, including high risk of bias related to outcome missing data, it was found that nonpharmacological interventions seemed to be more efficacious than pharmacological interventions for reducing aggression and agitation in adults with dementia. However, the study did not evaluate the harm and costs of the analyzed therapies. The effectiveness of non-pharmacological methods in managing agitation in patients with dementia has also been confirmed elsewhere (Leng et al., 2020).

Another assessment of the comparative efficacy and safety of pharmacological and non-pharmacological therapies for treating BPSD (Jin and Liu, 2019) based on data from 146 randomized trials comprising 44,873 patients found that the antipsychotics aripiprazole, haloperidol, quetiapine, and risperidone demonstrated significant efficacy compared to placebo, while memantine, galantine, and donepezil have had the least. Importantly, all drugs were found to demonstrate acceptable safety, and the authors conclude that drug therapy should be the first option in the treatment of BPSD.

Similar results were obtained from a Bayesian network meta-analysis on the efficacy of cholinesterase inhibitors in patients with mild-to-moderate AD by Kobayashi et al. (2016) who conclude that ChEIs should have significant efficacy for cognition and global change assessment, but the efficacy on BPSD is questionable.

PROMISING THERAPEUTIC OPTIONS OF BPSD

As current strategies for the management of NPSs often lack effectiveness, there is a need to identify other treatment options. Although most studies focus on pharmacological interventions, some involve techniques known for their efficacy in a other clinical field. Noninvasive brain stimulation methods such as repetitive transcranial magnetic stimulation, (rTMS) and transcranial direct current stimulation (tDCS) have been tested in depression, schizophrenia, autism, and cognitive deficits in AD and MCI (Wei et al., 2017; Barahona-Corrêa et al., 2018; Cruz Gonzalez et al., 2018; Osoegawa et al., 2018). A meta-analysis of randomized controlled trials found rTMS protocols to demonstrate efficacy but not tDCS (Vacas et al., 2018); however, both were found to demonstrate safety and tolerability in the studied population.

SUMMARY

BPSD are a significant problem in everyday clinical practice due to the prevalence, severity of symptoms, burden on the caregiver, and difficulties in treatment. Many existing clinical guides recommend the use of non-pharmacological methods as the first course of action, and that pharmacotherapy should be used as a secondary option or when there is severe presentation of symptoms. In practice, a range of drugs are used, although most are antipsychotics. Unfortunately, many of the pharmacological options lack strong evidence from clinical trials confirming their effectiveness, and many others are used as off-label treatments.

AUTHOR CONTRIBUTIONS

RM and TS determined the outline. RM, ES, and DR reviewed the literature and wrote the manuscript. TS and DR reviewed and approved the manuscript.

FUNDING

Swedish Research Council (Drn 2012-2291) by grants provided by the Stockholm County Council (ALF project) and CIMED. None of the sponsors had any involvement in the design of the study, the data collection or analysis, the writing of the report or the decision to submit the paper for publication.
REFERENCES

Abrahao, I., Rimland, J. M., Trota, P. F., Dell’Aquila, G., Cruz-Jentoft, A., Petrovic, M., et al. (2017). Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series. BMJ Open 7 (3), e012759. doi: 10.1136/bmjopen-2016-012759

Azermai, M., Petrovic, M., Elseviers, M. M., Bourgeois, J., Van Bortel, L. M., and Vander Stichele, R. H. (2012). Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Aging Res. Rev. 11 (1), 78–86. doi: 10.1016/j.arr.2011.07.002

Bailon, S. F., Narayana, U., Luxenberg, J. S., and Clifton, A. V. (2018). Valproate preparations for agitation in dementia. Cochrane Database Syst. Rev. 10, CD003945. doi: 10.1002/14651858.CD003945.pub4

Ballard, C., Orrell, M., Sun, Y., Moniz-Cook, E., Stafford, J., Whitaker, R., et al. (2019). Pimavanserin in agitation and psychosis in dementia. Aging Ment. Health 22 (2), 184–190. doi: 10.1080/13607863.2018.1531379

Bennett, S. and Thomas, A. J. (2014). Depression and dementia: cause, consequence or coincidence? Maturitas 79 (2), 184–190. doi: 10.1016/j.maturitas.2014.05.009

Bombois, S., Derambure, P., Pasquier, F., and Monaca, C. (2010). Sleep disorders in aging and dementia. J. Nutr. Health Aging 14 (3), 212–217. doi: 10.1007/s12603-010-0052-7

Borsje, P., Wetzels, R. B., Lucassen, P. L., Pot, A. M., and Koopmans, R. T. (2015). The course of neuropsychiatric symptoms in community-dwelling patients with dementia: a systematic review. Int. Psychogeriatr. 27 (3), 385–403. doi: 10.1017/S1041610214002282

Breite, M. H., Brounick, K., Chwischuk, L. I., Hynynen, M. J., Aarsland, D., and Rongve, A. (2018). Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies. Alzheimers Res. Ther. 10 (1), 83. doi: 10.1186/s13195-018-0416-5

Broadty, H., and Arasaratsam, C. (2012). Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am. J. Geriatr. Psychiatry 19 (10), 946–953. doi: 10.1016/j.jgp.2011.10.029

Bubu, O. M., Bramnick, M., Mortimer, J., Umasabor-Bubu, O., Sebastião, Y. V., Wen, Y., et al. (2017). Sleep, Cognitive impairment, and Alzheimer’s disease: A Systematic Review and Meta-Analysis. Sleep 40 (1), doj: 10.1093/sleep/zow032

Cabrera, E., Sutcliffe, C., Verheek, B., Saks, K., Soto-Martin, M., Meyer, G., et al. (2015). Non-pharmacological interventions as a best practice strategy in people with dementia living in nursing homes. A systematic review. Eur. Geriatr. Med. 6, 134–150. doi: 10.1111/ejger.2014.06.003

Caddell, L. S., and Clare, L. (2011). Interventions supporting self and identity in people with dementia: A systematic review. Aging Ment. Health 15 (7), 797–810. doi: 10.1080/13607863.2011.575352

Callegari, I., Mattei, C., Benassi, F., Krueger, F., Grafman, J., Yaldizli, O., et al. (2016). Agomelatine Improves Apathy in Frontotemporal Dementia. Neurol. Neurosci. Dis. 16 (5-6), 352–356. doi: 10.1159/000458783

Camargo, C. H. F., Serpa, R. A., Matnei, T., Sabatini, J. S., and Teive, H. A. G. (2016). The perception of apathy by caregivers of patients with dementia in Parkinson’s disease. Dement. Neuropsychol. 10 (4), 339–343. doi: 10.1590/s1980-5764-2016dn1004014

Caspar, S., Davis, E. D., Douzic, A., and Scott, D. R. (2018). Nonpharmacological Management of Behavioral and Psychological Symptoms of Dementia: What Works, in What Circumstances, and Why? Innov. Aging 2 (1), igy001. doi: 10.1093/geronj/gy001

Clare, L. (2003). Managing threats to self awareness in early stage Alzheimer’s disease. Soc. Sci. Med. 57 (6), 1017–1029. doi: 10.1016/S0277-9536(02)00476-8

Colenda, C. C., Mickus, M. A., Marcus, S. C., Tanielian, T. L., and Pincus, H. A. (2002). Comparison of adult and geriatric psychiatric practice patterns: findings from the American Psychiatric Association’s Practice Research Network. Am. J. Geriatr. Psychiatry 10 (5), 609–617. doi: 10.1016/S0961-8587(01)00041-6

Craig, C., Tennenbaum, C., Ducrèut, T., and Moride, Y. (2016). Patterns of antipsychotic use among community-dwelling elderly patients with dementia: impact of regulatory warnings. Med. Safe. Glob. Heal. 5 (129), 2. doi: 10.4172/2574-0407.1000129

Cummings, J., Isaacson, S., Mills, R., Williams, H., Chi-Burris, K., Corbett, A., et al. (2014). Pimavasin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383 (9916), 533–540. doi: 10.1016/S0140-6736(13)62106-6

Davies, S. J., Burhan, A. M., Kim, D., Gerretsen, P., Graff-Guerrero, A., Woo, V. L., et al. (2018). Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia. J. Psychopharmacol. 32 (5), 509–523. doi: 10.1177/0269881117744996

De Deyn, P., Jeste, D. V., Swanink, R., Kostic, D., Breder, C., Carson, W. H., et al. (2005). Aripiprazole for the treatment of psychosis in patients with Alzheimer’s disease: a randomized, placebo-controlled study. J. Clin. Psychopharmacol. 25 (5), 463–467. doi: 10.1097/01.jcp.0000178415.223069.8f

Deakin, J. B., Rahman, S., Nester, P. J., Hodges, J. R., and Sahakian, B. J. (2004). Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl.) 172 (4), 400–408. doi: 10.1007/s00213-003-1666-5

DeClercq, T., Petrovic, M., Azermay, M., Vander Stichele, R., De Sutter, A. J. M., van Driel, M. L., et al. (2013). Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst. Rev. (3), CD007726. doi: 10.1002/14651858.CD007726.pub2

den Brok, M. G., van Dalen, J. W., van Gool, W. A., Moll van Charante, E. P., de Bie, R. M., and Richard, E. (2015). Apathy in Parkinson’s disease: A systematic review and meta-analysis. Mov. Disorder. 30 (6), 759–769. doi: 10.1002/mds.26208

Desai, V. C., Heaton, P. C., and Kelton, C. M. (2012). Impact of the Food and Drug Administration’s antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings. Alzheimers Dement. 8 (5), 453–457. doi: 10.1016/j.jalz.2011.08.004

Ducharme, S., Price, B. H., and Dickerson, B. C. (2018). Apathy: a neuropsychiatric model based on frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 89 (4), 389–396. doi: 10.1136/jnnp-2017-316277

Dudas, R., Malouf, R., McClery, J., and Dening, T. (2018). Antidepressants for treating depression in dementia. Cochrane. Database. Syst. Rev. 8, CD03944. doi: 10.1002/14651858.CD003944.pub2

Dyer, S. M., Harrison, S. L., Laver, K., Whitehead, C., and Crotty, M. (2018). An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of
the CitAD randomized clinical trial. JAMA 311 (7), 682–691. doi: 10.1001/jama.2014.93

Porter, C. N., Miller, M. C., Lane, M., Cormann, C., Sarsour, K., and Kahle-Wrobleski, K. (2016). The influence of caregivers and behavioral and psychological symptoms on nursing home placement of persons with Alzheimer’s disease: A matched case-control study. SAGE Open Med. 4, 205031211661877. doi: 10.1177/205031211661877

Ralph, S. J., and Espinet, A. J. (2018). Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care. J. Alzheimers Dis. Rep. 2 (1), 1–26. doi: 10.3233/ADR-170042

Rattinger, G. B., Schwartz, S., Mullins, C. D., Corcoran, C., Zackman, I. H., Sanders, C., et al. (2015). Dementia severity and the longitudinal costs of informal care in the Cache County population. Alzheimers Dement. 11 (8), 946–954. doi: 10.1016/j.jalz.2014.11.004

Rattinger, G. B., Sanders, C. L., Vernon, E., Schwartz, S., Behrens, S., Lyketsos, C. G., et al. (2019). Neuropsychiatric symptoms in patients with dementia and the longitudinal costs of informal care in the Cache County population. Alzheimers Dement. (N. Y.) 5, 81–88. doi: 10.1016/j.trci.2019.01.002

Remington, R., Bechtel, C., Larsen, D., Samar, A., Doshanjh, L., Fishman, P., et al. (2015). A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer’s Disease. J. Alzheimers Dis. 45 (2), 395–405. doi: 10.3233/JAD-142499

Rus, V. J., Fochtmann, L. J., Fytler, A. E., Hilty, D. M., Horvitz-Lennon, M., Jibson, M. D., et al. (2016). The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. Am. J. Psychiatry 173 (5), 543–546. doi: 10.1176/appi.ajp.2015.173501

Rios, S., Perlman, C. M., Costa, A., Heckman, G., Hirdes, J. P., and Mitchell, L. (2017). Antipsychotics and dementia in Canada: a retrospective cross-sectional study of four health sectors. BMC Geriatr. 17 (1), 244. doi: 10.1186/s12877-017-0636-8

Rocha, F. L., Haro, C., Ramos, M. G., Kascher, G. G., Santos, M. A., de Oliveira Lança, G., et al. (2006). An exploratory open-label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia. Dement. Geriatr. Cogn. Disord. 22 (3–4), 445–448. doi: 10.1159/000095804

Roth, H. L. (2012). Dementia and sleep. Neurol. Clin. 30 (4), 1213–1248. doi: 10.1016/j.ncl.2012.08.013

Rozum, W. J., Cooley, B., Vernon, E., Matyi, J., and Tschanz, J. T. (2019). Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice. Drug Saf. 40 (6), 679–692. doi: 10.1007/s40264-017-0538-x

Streim, J. E., Porsteinsson, A. P., Breder, C. D., Swainik, R., Marcus, R., McQuade, R., et al. (2008). A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 16 (7), 537–550. doi: 10.1097/JGP.0b013e318165db77

Sugawara Kikuchi, Y., and Shimizu, T. (2019). Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series. Neuropsychiatr. Dis. Treat. 15, 543–547. doi: 10.2147/NPD.T219050

Sultzter, D. L., Davis, S. M., Tariot, P. N., Dagerman, K. S., Lebowitz, B. D., Lyketsos, C. G., et al. (2008). Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am. J. Psychiatry 165 (7), 844–854. doi: 10.1176/appi.ajp.2008.07111779

Taragano, F. E., Allegri, R. F., Krupitzki, H., Sarasola, D. R., Serrano, C. M., Loñ, L., et al. (2009). Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J. Clin. Psychiatry 70 (4), 584–592. doi: 10.4088/JCP.08m04181

Taragano, F. E., Allegri, R. F., Hurvitz, H., Sarasola, D. R., Serrano, C. M., Loñ, L., et al. (2009). Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J. Clin. Psychiatry 70 (4), 584–592. doi: 10.4088/JCP.08m04181

Theleritis, C., Barkos, K., Politis, A. O., and Politis, A. (2018). Risk of Conversion to Dementia in a Mild Behavioral Impairment Group Compared to a Psychiatric Group and to a Mild Cognitive Impairment Group. J. Alzheimers Dis. 62 (1), 227–238. doi: 10.3233/JAD-170832

Terun, T. M., Andersen, J. R., Rongve, A., Aarsland, D., Svendsboe, E. J., and Testad, I. (2017). The relationship of specific items on the Neuropsychiatric Inventory to caregiver burden in dementia: a systematic review. Int. J. Geriatr. Psychiatry 32 (7), 703–717. doi: 10.1002/gps.4704

Theletritis, C., Barkos, K., Politis, A. O., and Politis, A. (2018). A systematic review of non-pharmacological treatments for apathy in dementia. Int. J. Geriatr. Psychiatry 33 (2), e177–e192. doi: 10.1002/gps.4783

Trachtenberg, R. E., Weiner, M. F., Patterson, M. B., Teri, L., and Thal, L. J. (2003). Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer’s disease. J. Geriatr. Psychiatry Neurol. 16 (2), 94–99. doi: 10.1177/016188280301600206

Trachtenberg, R. E., Singer, C. M., and Kaye, J. A. (2005). Symptoms of sleep disturbance in persons with Alzheimer’s disease and normal elderly. J. Sleep Res. 14 (2), 177–185. doi: 10.1111/j.1365-2869.2005.00445.x
Trzepacz, P. T., Cummings, J., Kornechik, T., Forrester, T. D., Chang, C., Denney, E. B., et al. (2013). Milbemprob (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease. Int. Psychogeriatr. 25 (5), 707–719. doi: 10.1017/S1041610212002141

Vacas, S. M., Stella, F., Loureiro, J. C., do Couto, F. S., Oliveira-Maia, A. J., and Folenz, O. V. (2018). Noninvasive brain stimulation for behavioural and psychological symptoms of dementia: A systematic review and meta-analysis. Int. J. Geriatr. Psychiatry 34 (9), 1336–1345. doi: 10.1002/gps.5003

van der Linde, R. M., Stephan, B. C., Savva, G. M., Dening, T., and Brayne, C. (2012). Systematic reviews on behavioural and psychological symptoms in the older or demented population. Alzheimers Res. Ther. 4 (4), 28. doi: 10.1186/alzr1131

van der Linde, R. M., Dening, T., Stephan, B. C., Prina, A. M., Evans, E., and Brayne, C. (2016). Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. Br. J. Psychiatry 209 (5), 356–377. doi: 10.1192/bjp.bp.114.148403

van der Spek, K., Gerritsen, D. L., Smalbrugge, M., Nelis-Vrancken, M. H., Wetzels, R. B., Smeets, C. H., et al. (2016). Only 10% of the psychotropic drug use for neuropsychiatric symptoms in patients with dementia is fully appropriate. The PROPER I-study. Int. Psychogeriatr. 28 (10), 1589–1595. doi: 10.1017/S104161021600082X

Van Leeuwen, E., Petrovic, M., van Driel, M. L., De Sutter, A. I., Vander Stichele, R., Declercq, T., et al. (2018). Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst. Rev. 3, CD007726. doi: 10.1002/14651858.CD007726.pub3

Vandepitte, S., Putman, K., Van Den Noortgate, N., Verhaeghe, S., Mormont, E., Van Wilder, L., et al. (2018). Factors Associated with the Caregivers’ Desire to Institutionalize Persons with Dementia: A Cross-Sectional Study. Dement. Geriatr. Cogn. Disord. 46 (5–6), 298–309. doi: 10.1159/000494023

Wang, I. Y., Shofer, J. B., Rohde, K., Hart, K. L., Hoff, D. J., McFall, Y. H., et al. (2009). Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am. J. Geriatr. Psychiatry 17 (9), 744–751. doi: 10.1097/JGP.0b013e3181a8b6c1

Wang, G., Albayrak, A., and van der Cammen, T. J. M. (2018). A systematic review of non-pharmacological interventions for BPSD in nursing home residents with dementia: from a perspective of ergonomics. Int. Psychogeriatr. 18, 1–13. doi: 10.1017/S1041610218001679

Wang, Y. C., Tai, P. A., Poly, T. N., Islam, M. M., Yang, H. C., Wu, C. C., et al. (2018). Increased Risk of Dementia in Patients with Antidepressants: A Meta-Analysis of Observational Studies. Behav. Neurol. 2018, 5315098. doi: 10.1155/2018/5315098

Watt, J. A., Goodarzi, Z., Veroniki, A. A., Nincic, V., Khan, P. A., Ghassemi, M., et al. (2019). Comparative Efficacy of Interventions for Aggressive and Agitated Behaviors in Dementia: A Systematic Review and Network Meta-analysis. Ann. Intern. Med. 171, 633–642. doi: 10.7326/M19-0993

Weitnraub, D., Drye, L. T., Porsteinsson, A. P., Rosenberg, P. B., Pollock, B. G., Devanand, D. P., et al. (2015). Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. Am. J. Geriatr. Psychiatry 23 (11), 1127–1133. doi: 10.1016/j.jagp.2015.05.006

Wühlker, A., Zwakhalen, S. M., Challis, D., Suhonen, R., Karlsson, S., Zabaleguri, A., et al. (2015). Costs of care for people with dementia just before and after nursing home placement: primary data from eight European countries. Eur. J. Health Econ. 16 (7), 689–707. doi: 10.1007/s10198-014-0620-6

Yunusa, I., Alsulami, A., Garba, A. E., Regestein, Q. R., and Eguale, T. (2019). Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis. JAMA Netw. Open 2 (3), e190828. doi: 10.1001/jamanetworkopen.2019.0828

Zwijsen, S., Van der Ploeg, E., and Hertogh, C. (2016). Understanding the world of dementia. How do people with dementia experience the world? International Psychogeriatrics 28 (7), 1067–1077. doi: 10.1017/S1041610216003051

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Magierski, Sobow, Schwertner and Religa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.